Effect of a sibutramine/metformin combination on anti-Mffllerian hormone level, carbohydrate and lipid metabolisms in therapy for polycystic ovary syndrome in women with metabolic syndrome


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the clinical efficacy of reduxin met (Promomed, Russia) on anti-Müllerian hormone (AMH) level, carbohydrate and lipid metabolisms in patients with polycystic ovary syndrome (POS) and metabolic syndrome. Subjects and methods. Sixty patients aged 22 to 35 years (mean age, 28.7±5.2 years) with POS and verified metabolic syndrome (impaired tolerance glucose), were examined. The effects of different drugs on AMH level and carbohydrate and lipid metabolisms were comparatively analyzed. Results. During therapy with reduxin met, the values of AMH decreased from 8.8±1.6 ng/mg at baseline to 5.4±1.2 ng/ml after 3 months of therapy (p<0.01). This drug had a favorable effect on the blood lipid spectrum and carbohydrate metabolism following 3 months of its use, by reducing the level of total cholesterol and its atherogenic fractions and by normalizing carbohydrate metabolism. Conclusion. The decrease in AMH levels and the normalization of carbohydrate and lipid metabolisms in women with POS and metabolic syndrome during sibutramine/metformin hydrochloride combination therapy lead to the conclusion that this combination positively and effectively affects the above-mentioned parameters and ovulatory dysfunction through insulin-mediated mechanisms.

Full Text

Restricted Access

About the authors

Elena N. Andreeva

Endocrinology Research Center, Ministry of Health of Russia

Ph.D., Professor, Head of the Department of Endocrine Gynecology, with a group of screening and prevention of reproductive disorders

Olga R. Grigoryan

I.M. Sechenov First Moscow State Medical University

Email: iceberg1995@mail.ru
MD, main researcher, Endocrine Gynecology department with a group of screening and prevention of reproductive disorders

Natalia N. Volevodz

I.M. Sechenov First Moscow State Medical University

MD, professor, deputy director of preclinical diagnosis

Galina A. Melnichenko

Endocrinology Research Center, Ministry of Health of Russia

MD, professor, academician

References

  1. Jonard S., DeWailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum. Reprod. Update. 2004; 10(2): 107-17.
  2. Eldar-Geva T., Margalioth E.J., Gai M., Ben-Chetrit A., Algur N., Zylber-Haran E. et al. Serum anti-Müllerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum. Reprod. 2005; 20(7): 1814-9.
  3. Laven J.S., Mulders A.G., Visser J.A., Themmen A.P., de Jong F.H., Fauser B.C. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J. Clin. Endocrinol. Metab. 2004; 89(1): 318-23.
  4. Pigny P., Merlen E., Robert Y., Cortet-Rudelli C., Decanter C., Jonard S., Dewailley D. Elevated serum level of anti-Müllerian hormone inpatients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicle arrest. J. Clin. Endocrinol. Metab. 2003; 88(12): 5957-62.
  5. Piouka A., Farmakiotis D., Katsikis I., Macut D., Gerou S., Panidis D. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am. J. Physiol. Endocrinol. Metab. 2009; 296(2): E238-43.
  6. Carlsen S.M., Vanky E., Fleming R. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum. Reprod. 2009; 24(7): 1732-8.
  7. La Marca A., Orvieto R., Giulini S., Jasonni V.M., Volpe A., De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil. Steril. 2004; 82(4): 970-2.
  8. Nardo L.G., Yates A.P., Roberts S.A., Pemberton P., Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum. Reprod. 2009; 24(11): 2917-23.
  9. Viollet B., Guigas B., Sanz Garcia N., Leclerc J., Foretz M., Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond). 2012; 122(6): 253-70.
  10. Tang T., Lord J.M., Norman R.J., Yasmin E., Baien A.H. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Database Syst. Rev. 2012; (5): CD003053.
  11. Du Q., Wang Y.J., Yang S., Wu B., Han P., Zhao Y. Y. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr. Med. Res. Opin. 2012; 28(5): 723-30.
  12. Fleming R., Harborne L., MacLaughlin D.T., Ling D., Norman J., Sattar N., Seifer D.B. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil. Steril. 2005; 83(1): 130-6.
  13. Piltonen T., Morin-Papunen L., Koivunen R., Perheentupa A., Ruokonen A., Tapanainen J.S. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum. Reprod. 2005; 20(7): 1820-6.
  14. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004; 19(1): 41-7.
  15. Coutts J.R., Adam A.H., Fleming R. The deficient luteal phase may represent an anovulatory cycle. Clin. Endocrinol. (Oxf). 1982; 17(4): 389-94.
  16. Romualdi D., De Cicco S., Tagliaferri V., Proto C., Lanzone A., Guido M. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2011; 96(5): E821-4.
  17. Tomova A., Deepinder F., Robeva R., Kirilov G., Mechandjiev Z., Kumanov P. Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. Horm. Metab. Res. 2011; 43(10): 723-7.
  18. Thomson R.L., Buckley J.D., Moran L.J., Noakes M., Clifton P.M., Norman R.J., Brinkworth G.D. The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum. Reprod. 2009; 24(8): 1976-81.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies